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Abstract
The majority of cancer treatments end in failure due to Intra-Tumor Heterogeneity
(ITH). ITH in cancer is represented by clonal evolution where different sub-clones
compete with each other for resources under conditions of Darwinian natural
selection. Predicting the growth of these sub-clones within a tumour is among
the key challenges of modern cancer research. Predicting tumor behavior enables
the creation of risk profiles for patients and the optimisation of their treatment
by therapeutically targeting sub-clones more likely to grow. Current research
efforts in this space are focused on mathematical modelling of population genetics
to quantify the selective advantage of sub-clones, thus enabling predictions of
which sub-clones are more likely to grow. These tumor evolution models are
based on assumptions which are not valid for real-world tumor micro-environment.
Furthermore, these models are often fit on a single instance of a tumor, and hence
prediction models cannot be validated.
This paper presents an alternative approach for predicting cancer evolution using
a data-driven machine learning method. Our proposed method is based on the
intuition that if we can capture the true characteristics of sub-clones within a tumor
and represent it in the form of features, a sophisticated machine learning algorithm
can be trained to predict its behavior. The steps implemented in our approach are:
• Longitudinal data acquisition - labelled longitudinal data, with known outputs
for validations, from the TRACERx lung cancer liquid biopsy study to apply
machine learning and predict cancer evolution.
• Sub-clonal profiling - Inference of the number of sub-clones, and the number
of mutations within each sub-clone, for each tumor.
• Feature selection - Features which can truly represent sub-clones characteris-
tics were identified. Based on mutation location we extracted several features
including functional impact, properties of genes where mutations occur, and
the properties of associated proteins and their interactions with other proteins.
• Feature representation as a fixed-length vector - Different sub-clones have
different number of mutations and feature representation at a mutation level
needed to be aggregated at a sub-clone level to be used by a model.
• Machine learning model - Both regression analysis (to predict the amount of
growth or reduction of each sub-clone in future) and classification analysis
(to predict if a sub-clone will grow or not in future) were applied. With
regression analysis we obtained an R2 of 0.14 and with classification analysis
we obtained anAUC−ROC of >0.6. Both were better than mean and random
predictions respectively showing predictive strength in cancer evolution.
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The work presented here provides a novel approach to predicting cancer evolution,
utilizing a data-driver approach. We strongly believe that the accumulation of data
from microbiologists, oncologists and machine learning researchers could be used
to encapsulate the true essence of tumor sub-clones, and can play a vital role in
selecting the best cancer treatments for patients.
1 Introduction
Cancer is an evolutionary process where cellular sub-populations known as sub-clones compete with
each other under conditions of Darwinian natural selection[1]. Resultant Intra-Tumor Heterogeneity
(ITH) has been associated with higher likelihood of relapse and increased resistance to therapy in
cancer patients[2, 3]. The ability to precisely predict how these sub-clones will evolve over time can
help clinicians to develop an effective cancer treatment and reduce treatment failures[4].
Tumor evolution in literature has mostly been addressed through the mathematical modelling approach.
One early analytical approach is based on using models from population genetics to quantify the
selective advantage of sub-clones, thus enabling predictions of which sub-clones are more likely
to grow [5]. Until recently, it was almost impossible to observe the clonal growth at different time
points due to the invasive nature of tissue biopsies. Therefore, the analysis of tumour growth and
mutation frequencies was normally conducted at one time point - from the excised tumour sample.
Next Generation Sequencing (NGS) methods such as targeted sequencing or full exome sequencing,
followed by variant calling algorithms, allow the calculation of Variant Allele Frequencies (VAFs) in
a sample. A number of quantitative models have been developed to infer the evolutionary events that
generated the resulting distribution of allele frequencies [6, 7]. These methods allow us to determine
whether there is selection occurring in the tumour by analysing the VAF spectra.
All of these tumor evolution models are validated either by fitting the mathematical model on a single
instance of tumor VAFs or by using simulated material. The validations of these models were not
done on real-world longitudinal samples.
In this paper, we present a novel data-driven approach to predict cancer evolution for real-world
data. Our proposed method is based on the intuition that if we can capture the true characteristics of
sub-clones within a tumor and represent it in the form of features, a sophisticated machine learning
algorithm can be trained to predict its behavior. Our main challenges are as follows:
• Accurately identifying the number of sub-clones and their formation and constitution in a
given tumor.
• Feature-based representation of sub-clones to encapsulate the characteristics of underlying
mutations towards tumorigenesis.
• Gathering labelled data across timepoints for application of machine learning models to
predict evolution.
2 Methods
Figure 1: An overview of the proposed method
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2.1 Data acquisition and pre-processing
We used longitudinal data from the TRACERx lung cancer liquid biopsy study by Abbosh et al.
(2017).[8]. This includes data from 24 patients monitored for 1-3 years. For these patients, DNA
mutational data was generated by liquid biopsy (2-8 samples per patient) and subclonal information
was generated with PyClone[9].
2.2 Feature extraction
Features were extracted at three levels: mutation, codon, and gene (Figure 2).
For mutation-level features we utilized the Ensembl Variant Effect Predictor[10], which provides
individual scores around likely consequences and potential impacts for a given mutation, including
scores predicting protein effect such as SIFT and PolyPhen.
For codon-level features we applied a statistical model to data from large-scale genomics projects,
The Cancer Genome Atlas [11] and Genie [12], to give a hotspot score per codon based on frequency
of observed mutations against background mutability.
For gene-level features we utilized the various scores and metrics produced by the 20/20+ tool
[13], which calculates these as part of a machine-learning-based ratiometric method of driver-gene
classification through evaluation of the proportion of inactivating mutations and recurrent missense
mutations in a gene of interest.
Figure 2: Final features extracted
2.3 Feature selection and integration
As different sub-clones have differing numbers of mutations, statistical features including mean, max,
min and median were calculated from the sets of mutations to give fixed length feature vectors to
represent the sub-clones. The final form of the features matrix is as follows:
features_matrix =
x11 . . . x1f... . . . ...
xc1 . . . xcf
 c : number of sub-clonesf : number of features
2.4 Model training and evaluation
Clonal-evolution within a tumor is predicted using two approaches: a regression analysis and a
classification analysis. We evaluate both approaches with a range of algorithms, hyperparameter
optimization, and K-fold cross validation at k=5.
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3 Results
3.1 Regression Analysis
A random forest regression analysis returned promising results (Figure 3). Overall, an R2 of 0.16
was achieved. Although there is much to be improved in terms of model performance, this shows
promising signal, indicating a better than random performance.
Figure 3: Predicting change in VAF over time (Days) for four randomly chosen sub-clones
3.2 Classification Analysis
As a classification problem the approach is simplified greatly, with the goal of simply predicting if
the sub-clonal VAF will increase or decrease. Classification methods used were logistic regression,
random forest, support vector machine (SVM) and artificial neural network, respectively. We present
results for predicting change of sub-clones, PCA of sub-clones, and driver mutations, respectively
(Table 1).
Table 1: Performance summary of classification models (ROC-AUC; F1 score)
Logistic Regression Random Forest SVM ANN
Sub-clones 0.298; 0.399 0.354; 0.333 0.422; 0.389 0.512; 0.623
PCA sub-clones 0.456; 0.519 0.573; 0.527 0.511; 0.476 0.505; 0.421
Driver mutations 0.618; 0.348 0.785; 0.643 0.566; 0.488 0.511; 0.364
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4 Conclusions & Future Work
In this paper, we have shown that is possible to predict the course of tumor evolution using prior
information. This has profound implications in the clinical management of cancer as a chronic
disease. Interestingly, our models performed best on ’driver’ mutations, i.e. those thought to be
primarily responsible for driving clonal growth. This adds weight to the biological significance of the
results.
Clearly there is much to be improved in terms of model performance. Current and future work by
our group will include greater data collection, applying improved liquid biopsy analytical methods
developed by Cambridge Cancer Genomics, and further refinement of the evolutionary model choice,
which was found to greatly influence performance. Overall, this enable more accurate prediction of
cancer evolution through data-driven machine learning approaches, and ultimately greatly improve
cancer care.
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